CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-09. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
FDA pediatric label expansion broadens Casgevy addressable patient population, driving sequential revenue growth for CRSP and partner VRTX.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factCasgevy sales grew 78% quarter-over-quarter to reach $76 million in Q2. |
| What else was confirmed? | Reported factThe FDA granted label expansion for Casgevy covering pediatric patients aged 2 and older. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for CRSP yet — this is the next research task. |
| What would change the assessment? | UnknownCasgevy Q3 Treatment Center Onboarding — Patient enrollment figures following pediatric label expansion. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Casgevy sales grew 78% quarter-over-quarter to reach $76 million in Q2.
- · The FDA granted label expansion for Casgevy covering pediatric patients aged 2 and older.
- · CRISPR Therapeutics shares gained nearly 19% in August following earnings results.
Public research record
Research framework · page evidenceCompleted event assessment
commercial revenue growth from regulatory label expansion
| Type | Claim | Scope |
|---|---|---|
| Assumption | Casgevy sales grew 78% quarter-over-quarter to reach $76 million in Q2. | 2026-09-09 |
| Interpretation | commercial revenue growth from regulatory label expansion | CRSP |
Countercase, invalidators, and sources
Pediatric patient onboarding ramps through Q3, accelerating Casgevy run-rate past $100M quarterly.
- · Casgevy Q3 Treatment Center Onboarding — Patient enrollment figures following pediatric label expansion.
- Why CRISPR Therapeutics Stock Rocked the Market Last Month · 2026-09-08
What remains unresolved
- Base path
- Commercial adoption continues steady growth across specialized treatment centers.
- Adverse path
- Reimbursement delays and complex cell processing cycles constrain sequential adoption rates.
- Supportive path
- Pediatric patient onboarding ramps through Q3, accelerating Casgevy run-rate past $100M quarterly.
- · Casgevy Q3 Treatment Center Onboarding — Patient enrollment figures following pediatric label expansion.next month
Evidence
- Why CRISPR Therapeutics Stock Rocked the Market Last Month2026-09-08
“CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older.”
Supports: Casgevy Q2 sales rose 78% QoQ to $76M and FDA approved pediatric label expansion.